AGP Executive Report

Abortion Law Debate in Liechtenstein: A new push to legalize abortion is again colliding with the country’s strict rules, with reporting pointing to Hereditary Prince Alois’s past use of royal veto power as a key barrier. Hepatitis B Research Hope: European researchers are pursuing a “functional cure” for chronic hepatitis B, noting that millions in the EU/EEA (including Liechtenstein) live with the infection without realizing it until serious liver damage. Oncology Deal With Liechtenstein in the Territory: IMPACT Therapeutics and Pharmanovia signed an exclusive licensing agreement for senaparib across 66 countries, explicitly including Liechtenstein, aiming to speed access for advanced ovarian cancer maintenance therapy. Patient Safety & Counterfeit Dental Products: Ivoclar is rolling out a verification program to help dental professionals avoid risks from gray-market and counterfeit products that can undermine treatment safety. Data Breach Alert (Healthcare): Brown Health Medical Group-MA says 311,000 people were affected by a breach involving stolen personal and medical-related records.

Abortion Rights in Focus (Liechtenstein): A new push to modernise Liechtenstein’s very strict abortion rules is again colliding with the royal veto power, with reporting pointing to Hereditary Prince Alois as the key obstacle to legal change. Cancer Care Deal (Liechtenstein-linked): IMPACT Therapeutics and Pharmanovia signed an exclusive licensing agreement for senaparib, aiming to expand access across 66 countries, including Liechtenstein, with payments potentially reaching €423.5m. Public Health Research (Hepatitis B): European experts highlight the gap between a long-available hepatitis B vaccine and the lack of a cure for people already living with chronic infection, noting millions affected across the EU plus Liechtenstein and Norway. Food Safety at Borders (Liechtenstein travellers): UK guidance warns travellers returning from EU countries, including Liechtenstein, that bringing back meat and dairy is restricted and can trigger fines or prosecution. Healthcare Data Breach (US): Brown Health Medical Group-MA says a breach exposed sensitive personal and medical data for 311,000 people.

Water & Wellness Business: Dropvital (Dropvital AG, Schaan) is positioning itself as a trust-first water-treatment brand, combining hands-on filtration installation experience with certified organic medicinal mushroom know-how and manufacturer-independent service support. Cancer Drug Access: IMPACT Therapeutics and Pharmanovia signed an exclusive licensing deal for senaparib, aiming to expand the ovarian cancer maintenance therapy across 66 countries, including Liechtenstein and the wider EU/UK/EEA markets, with payments up to €423.5m plus royalties. Public Health Research: A new push for a “functional cure” for chronic hepatitis B highlights ongoing work across Europe, noting millions in the EU/EEA (including Liechtenstein) live with infection without realizing it until serious liver damage. Patient Safety & Supply Chains: Ivoclar is rolling out a verification approach to reduce risks from counterfeit and gray-market dental products, warning that unofficial sourcing can mean expired or improperly handled materials. Local Policy Watch: Liechtenstein’s abortion law debate is resurfacing, with reporting focused on the role of Hereditary Prince Alois and the impact on access for people who would otherwise travel to Switzerland or Austria.

Cancer Drug Deal: IMPACT Therapeutics and Pharmanovia signed an exclusive licensing agreement for senaparib, aiming to expand the ovarian cancer maintenance therapy across 66 countries, including Liechtenstein and the wider EU, with payments up to €423.5m plus royalties. COVID-19 Update: Pfizer-BioNTech received EU marketing authorisation for an XFG-variant COVID-19 vaccine for people 6 months and older, with rollout planned for the respiratory season and coverage including Liechtenstein. Public Health Research: A new push for a “functional cure” for chronic hepatitis B highlights that vaccines prevent infection, but millions already living with the disease still need lifelong treatment. Patient Safety & Supply Chains: Ivoclar is rolling out a verification program to help dental professionals avoid counterfeit and gray-market products that can compromise safety and treatment outcomes. Local Health Risk: Brown Health Medical Group-MA is notifying 311,000 people after a December 2025 data breach exposed sensitive personal, medical, and financial records. Health Policy Debate (Liechtenstein): Commentary reports renewed pressure to modernise Liechtenstein’s abortion laws, with the royal veto power again raised as a key obstacle.

Cancer care licensing: IMPACT Therapeutics and Pharmanovia signed an exclusive deal worth up to €423.5m for senaparib across Europe (incl. Liechtenstein), UK, Norway, Iceland, Switzerland, Australia, New Zealand, and parts of MENA, aiming to speed access for ovarian/fallopian tube/primary peritoneal cancer patients. COVID-19 vaccination update: The European Commission authorized Pfizer-BioNTech’s XFG-adapted COVID-19 vaccine for people 6 months+, with coverage across EU plus Iceland, Liechtenstein, and Norway. Public health research: A new European push is targeting a “functional cure” for chronic hepatitis B, where millions in the EU/EEA (including Liechtenstein) are infected but often only learn after serious liver damage. Patient safety & counterfeit risk: Ivoclar rolled out a verification approach for authorized dental product distributors, warning that gray-market/counterfeit items can compromise treatment and patient safety. Reproductive health policy: Liechtenstein’s abortion law debate is back in focus, with reporting highlighting how royal veto power has blocked past liberalization efforts.

Abortion Law Update: Abortion activists are pushing another bid to modernise Liechtenstein’s strict abortion laws, but a hereditary prince has threatened to use his veto power again—echoing a past referendum defeat. Cancer Drug Deal: IMPACT Therapeutics and Pharmanovia signed an exclusive licensing agreement worth up to €423.5m, giving Pharmanovia rights to manufacture and commercialise senaparib across Europe (including Liechtenstein), plus parts of the Middle East and North Africa, Australia and New Zealand. COVID-19 Vaccines: The European Commission authorised Pfizer-BioNTech’s updated XFG-adapted COVID-19 vaccine for people 6 months and older, with validity across EU states plus Iceland, Liechtenstein and Norway. Hepatitis B Research: Researchers in Europe are working toward a “functional cure” for chronic hepatitis B, where today’s treatments can suppress the virus but can’t eliminate it; Liechtenstein is included in the EU-region infection estimates. Patient Safety & Counterfeits: Ivoclar is rolling out a verification approach for authorised dental product distributors to reduce risks from gray market and counterfeit items. Travel Insurance for Older People: Coverage options for older travellers are narrowing, with fewer insurers and stricter age limits shaping what people can buy.

Abortion Law Update (Liechtenstein): Abortion activists are pushing another bid to legalize abortion in Liechtenstein, but a hereditary prince says he will use his royal veto again—echoing the 2012 referendum that narrowly rejected legalization. Schengen & Migration: Italy’s push to suspend Spain from the Schengen zone over the Ceuta migrant surge is being challenged as effectively impossible under how Schengen works, though the debate is heating up across EU capitals. Cancer Drug Deal (Liechtenstein included): IMPACT Therapeutics and Pharmanovia signed an exclusive licensing agreement worth up to €423.5m for senaparib, expanding access across 66 countries including Liechtenstein, with EU regulatory review expected to support availability later in 2026. COVID-19 Vaccine (Liechtenstein included): The European Commission authorized Pfizer-BioNTech’s XFG-adapted COVID-19 vaccine for ages 6 months+, valid across the EU plus Iceland, Liechtenstein and Norway. Public Health Focus (Hepatitis B): A new push for a “functional cure” for chronic hepatitis B highlights that vaccines prevent infection, but millions already living with the disease still need lifelong treatment. Patient Safety (Counterfeit risk): Ivoclar is rolling out a verification approach for authorized dental distributors, warning that gray-market and counterfeit products can undermine safety and treatment outcomes.

Cancer Drug Deal: IMPACT Therapeutics and Pharmanovia signed an exclusive licensing agreement worth up to €423.5m for senaparib, a PARP1/2 inhibitor, covering manufacture, development and commercialization across 66 countries including Liechtenstein, with an EMA review for first-line ovarian cancer maintenance expected in the second half of 2026. COVID-19 Update: The European Commission granted marketing authorisation for Pfizer-BioNTech’s 2026–2027 COVID-19 vaccine adapted to the XFG variant, approved for EU states plus Iceland, Liechtenstein and Norway for people aged 6 months and older. Public Health Research: A new push for a “functional cure” for chronic hepatitis B highlights that vaccines prevent infection but don’t cure those already living with the disease; researchers say immune-targeting approaches may finally change outcomes. Patient Safety & Supply Chains: Ivoclar introduced a verification program for authorised dental product distributors, warning that counterfeit and gray market items can bypass safety standards and lead to compromised treatment or patient harm. Health Policy & Access: A report spotlights how Liechtenstein’s strict abortion laws can delay or block care, pushing some people to seek services across the border. Travel & Health Costs: Coverage on travel insurance for older people notes fewer options and tighter restrictions as age cut-offs rise. Border Rules Explained: A guide explains Schengen visa requirements for visiting Spain, listing Liechtenstein among the Schengen countries.

Abortion Access in Liechtenstein: A new report highlights how Liechtenstein’s strict abortion rules push people to cross borders for care, including added hurdles like upfront clinic fees and delays—leaving an estimated ~40 women each year unable to end pregnancies on their own terms. Schengen Shockwaves: Italy’s push to suspend Spain from the Schengen zone after migrant arrivals at Ceuta is met with a blunt reality check: shutting a country out isn’t straightforward, even as political pressure grows. Hepatitis B “Functional Cure” Hope: Researchers across Europe say a functional cure for chronic hepatitis B may be within reach, despite the fact that today’s antivirals suppress the virus but don’t eliminate it. Cancer Drug Deal for Liechtenstein Patients: Pharmanovia has licensed IMPACT’s senaparib for maintenance therapy in ovarian, fallopian tube, and primary peritoneal cancer across Europe and also includes Liechtenstein in its territory. COVID-19 Vaccine Update: The EU has authorized Pfizer-BioNTech’s XFG-adapted COVID-19 vaccine for people 6 months and older, with coverage including Liechtenstein. Patient Safety & Counterfeits: Dental manufacturer Ivoclar is rolling out verification steps to reduce risks from counterfeit and gray-market dental products that can bypass safety standards. Travel Insurance for Older People: Coverage for seniors is getting narrower, with fewer insurers and more restrictions as age-based risk rules tighten.

Hepatitis B Breakthrough: Researchers say a “functional cure” for chronic hepatitis B may finally be within reach, noting that while a vaccine exists, today’s antivirals can suppress but not eliminate the virus—millions in Europe (including Liechtenstein) are living with chronic infection. Patient Safety & Supply Chains: Dental manufacturer Ivoclar is rolling out a verification program to help clinics avoid counterfeit and gray-market dental products, warning that unofficial supply can mean expired or degraded materials and unsafe treatment outcomes. COVID-19 Protection Update: Pfizer-BioNTech received EU marketing authorization for a 2026–2027 COVID-19 vaccine adapted to the XFG variant, approved for people 6 months and older across EU states plus Iceland, Liechtenstein and Norway. Cancer Drug Deal: IMPACT Therapeutics and Pharmanovia signed an exclusive licensing partnership for senaparib across Europe and other regions including Liechtenstein, aiming at 1L maintenance therapy for advanced ovarian cancers, with regulatory review expected to progress in 2026. Local Health Governance: A Malta political controversy is spilling into government staffing, with a former insider reportedly recruited as a consultant at the Economy Ministry after a parliamentary privilege complaint tied to threats against an opposition MP.

Parliament & Workplace Conduct: Malta’s Economy Ministry has reportedly hired a veteran insider as a consultant despite his recent threats and intimidation toward Opposition MP Adrian Delia, after a parliamentary privilege complaint forced him to withdraw and apologise. Hepatitis B Research: New European work is pushing toward a “functional cure” for chronic hepatitis B, where today’s antivirals can suppress but not eliminate the virus; Liechtenstein is among the countries with millions living with chronic infection. Patient Safety & Supply Chains: Dental manufacturer Ivoclar is rolling out a verification program to steer clinics toward authorised distributors and away from counterfeit or gray-market products that can bypass safety checks. Cancer Drug Access: IMPACT Therapeutics and Pharmanovia signed an exclusive licensing deal for senaparib across Europe and several regions including Liechtenstein, aiming to expand maintenance therapy options for advanced ovarian-related cancers. COVID-19 Vaccines: The EU has authorised Pfizer-BioNTech’s XFG-adapted COVID-19 vaccine for people 6 months and older, with validity including Liechtenstein.

Dental Safety & Supply Chains: Ivoclar is rolling out a verification program to help dental professionals spot authorized distributors and avoid counterfeit or gray-market dental products that can bypass quality checks and risk patient harm. Oncology Drug Deal (EU/EEA + Liechtenstein): IMPACT Therapeutics has licensed senaparib to Pharmanovia for exclusive manufacturing, development and commercialization across the EU, UK, Norway, Iceland, Switzerland and Liechtenstein (plus MENA, Australia and New Zealand), with total deal value up to €423.5M and royalties tied to sales; the drug is aimed at 1L maintenance for advanced ovarian/fallopian tube/primary peritoneal cancer. COVID-19 Vaccination Update: The European Commission authorized Pfizer-BioNTech’s XFG-adapted COVID-19 vaccine for people 6 months and older, valid across EU plus Iceland, Liechtenstein and Norway, with manufacturing already underway for the respiratory season. Travel Insurance for Older People: A guide highlights fewer insurer options and tighter age limits for seniors, with some policies covering up to 79 and a few offering no upper age cap. Schengen Politics & Health Travel Impact: Debate continues over whether an EU country could be suspended from Schengen cooperation, with Liechtenstein included in the Schengen area and potential knock-on effects for cross-border travel planning.

Dental Safety: Ivoclar is rolling out a verification program to help dental professionals avoid risks from counterfeit and gray market dental products, which can bypass quality checks and lead to expired, damaged, or improperly handled items. Cancer Drug Deal: IMPACT Therapeutics has licensed senaparib to Pharmanovia for exclusive manufacture and commercialization across Europe (including Liechtenstein), the UK, Norway, Iceland, Switzerland, Australia, New Zealand, and parts of MENA, with up to €423.5M in payments and royalties tied to sales. COVID-19 Update: The European Commission authorized Pfizer-BioNTech’s XFG-adapted COVID-19 vaccine for people 6 months and older, valid across EU plus Iceland, Liechtenstein, and Norway, with manufacturing already underway for the upcoming respiratory season. Travel Insurance for Seniors: A new look at travel insurance finds fewer options and more restrictions for older travellers, with many policies cutting off around ages 65–70, though some insurers offer higher or no upper limits. Schengen Politics: Calls to suspend a country from the Schengen zone are back in the spotlight after debate over Spain’s handling of migrants at Ceuta, raising questions about how border-free rules could be enforced.

Cancer Care Deal: IMPACT Therapeutics and Pharmanovia signed an exclusive licensing partnership for senaparib, expanding the PARP drug beyond China into the EU, UK, Norway, Iceland, Liechtenstein, Switzerland, Australia, New Zealand, and parts of the Middle East and North Africa, with up to €423.5M in upfront and milestone payments plus royalties. COVID-19 Protection: The European Commission authorized Pfizer-BioNTech’s 2026–2027 XFG-adapted COVID-19 vaccine for people 6 months and older, valid across the EU plus Iceland, Liechtenstein, and Norway, with manufacturing already underway for the respiratory season. Travel & Health Costs: Older travellers face fewer travel insurance options and stricter rules, with many mainstream policies cutting off around 65–70, while some insurers offer coverage up to 79 or even no upper limit. Cardiovascular Drug Progress: NewAmsterdam Pharma received a positive CHMP opinion for Ubeslo (obicetrapib) and Evlarco (obicetrapib/ezetimibe) for primary hypercholesterolemia, with an EU decision expected in the second half of 2026. Policy Watch: A debate is growing over whether an EU country could be suspended from Schengen cooperation, raising fresh uncertainty for cross-border movement.

COVID-19 Vaccine Update for Liechtenstein: Pfizer-BioNTech’s XFG-adapted COVID-19 vaccine has received European Commission marketing authorisation for people aged 6 months and older, with coverage across EU states plus Iceland, Liechtenstein, and Norway—manufacturing is already underway to be ready for the respiratory season. Pharma Supply Shock in the US: A major US tariff plan would hit imported patented drugs at 100% and also targets generics on a staged timeline, raising concerns about costs and how quickly manufacturers can shift production. Cardiovascular Drug Progress in Europe: NewAmsterdam Pharma and Menarini report a positive CHMP opinion for Ubeslo® (obicetrapib) and Evlarco® (obicetrapib/ezetimibe) for certain high- LDL cholesterol patients, with an EU decision expected in 2H26. Local Health & Mobility Policy Watch: A UK benefits alert highlights strict reporting rules for PIP recipients taking trips longer than four weeks, warning that failing to notify could lead to penalties or payment suspension.

COVID-19 Vaccine Update: The European Commission has authorized Pfizer-BioNTech’s 2026–2027 COVID-19 vaccine adapted to the XFG variant for people aged 6 months and older, with approval valid across EU member states plus Iceland, Liechtenstein, and Norway. Pharma Access & Costs: A branded drug tariff change is set to reshape US pricing and supply for major companies, while generics face a separate multi-year tariff timeline. Cardiovascular Drug Pipeline: NewAmsterdam Pharma and Menarini received a positive CHMP opinion for Ubeslo® (obicetrapib) and Evlarco® (obicetrapib plus ezetimibe) aimed at lowering LDL-C in primary hypercholesterolemia, with an EU decision expected in 2H26. Medtech Funding in the Region: Healthcare Holding Schweiz AG closed CHF 80 million in syndicated financing to expand its independent medtech distribution and acquisition strategy, with Liechtenstein’s Landesbank among the lenders. Disability Benefits Reminder: The UK DWP warns PIP recipients that leaving the country for more than four weeks can trigger penalties unless they notify the agency. Work & Health Tech Careers: The UK Met Office is hiring junior software developers to support weather and climate services.